VRTX insider Mark Atkinson reports 2,500-share stock sale

Q: What insider transaction did VRTX report in this Form 4?

The Form 4 reports that Mark Atkinson , Executive Vice President and Chief Technical Operations Officer of Vertex Pharmaceuticals, sold 2,500 shares of Vertex common stock on 11/17/2025 .

Q: What is the role of the insider involved in this VRTX Form 4 filing?

The reporting person, Mark Atkinson , is identified as an Officer of Vertex Pharmaceuticals, serving as EVP, Chief Technical Ops. Off.

Q: Was the VRTX insider sale made under a Rule 10b5-1 trading plan?

Yes. The transaction was made pursuant to a company-approved trading plan under Rule 10b5-1 , which the filing states was entered into on 08/11/2025 .

Q: Is this VRTX Form 4 filed by one or multiple reporting persons?

The document indicates that the Form was filed by one reporting person , not a group filing.

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Vertex Pharmaceuticals (VRTX) executive Mark Atkinson reported a planned stock sale. As Executive Vice President and Chief Technical Operations Officer, he filed a Form 4 showing the sale of 2,500 shares of Vertex common stock on 11/17/2025 at a price of $434.58 per share.

After this transaction, he beneficially owned 16,852 shares directly. The filing notes that the sale was made under a company-approved Rule 10b5-1 trading plan that Mr. Atkinson entered into on 08/11/2025, meaning the trades were pre-arranged under SEC rules designed to allow insiders to sell shares according to a preset plan.

Insider Trade Summary

Net Seller: 2,500 shares

Net Sell 1 txn

Insider Atkinson Edward Morrow III

Role EVP, Chief Technical Ops. Off.

Sold 2,500 shs ($1.09M)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,500	$434.58	$1.09M

Holdings After Transaction: Common Stock — 16,852 shares (Direct)

Footnotes (1)

F1. Transaction made pursuant to Mr. Atkinson's company approved trading plan under Rule 10b5-1, which was entered into on 08/11/2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 11/19/2025 - 04:06 PM

FAQ

What insider transaction did VRTX report in this Form 4?

The Form 4 reports that Mark Atkinson, Executive Vice President and Chief Technical Operations Officer of Vertex Pharmaceuticals, sold 2,500 shares of Vertex common stock on 11/17/2025.

At what price were the VRTX shares sold by the executive?

The reported sale of Vertex common stock was executed at a price of $434.58 per share.

How many VRTX shares does the reporting person own after this transaction?

Following the reported sale, Mark Atkinson beneficially owned 16,852 shares of Vertex common stock, held directly.

What is the role of the insider involved in this VRTX Form 4 filing?

The reporting person, Mark Atkinson, is identified as an Officer of Vertex Pharmaceuticals, serving as EVP, Chief Technical Ops. Off.

Was the VRTX insider sale made under a Rule 10b5-1 trading plan?

Yes. The transaction was made pursuant to a company-approved trading plan under Rule 10b5-1, which the filing states was entered into on 08/11/2025.

Is this VRTX Form 4 filed by one or multiple reporting persons?

The document indicates that the Form was filed by one reporting person, not a group filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Atkinson Edward Morrow III

(Last)

(First)

(Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON

02210

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, Chief Technical Ops. Off.

3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/17/2025		S⁽¹⁾		2,500	D	$434.58	16,852	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Transaction made pursuant to Mr. Atkinson's company approved trading plan under Rule 10b5-1, which was entered into on 08/11/2025.

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	11/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR